Skip to main content

Table 1 Number of patients, PET–CTs and indication for PET–CTs according to sarcoma subtype

From: Retrospective audit of 957 consecutive 18F-FDG PET–CT scans compared to CT and MRI in 493 patients with different histological subtypes of bone and soft tissue sarcoma

Sarcoma pathological diagnosis

Number of patients

Number of PET–CT scans

Total

Staginga (with metastasis)

Restaging

Treatment response

Undifferentiated pleomorphicb

81

166

64 (6)

62

40

Angiosarcomac

8

11

7 (1)

3

1

Leiomyosarcoma

89

166

43 (8)

84

39

Rhabdomyosarcoma

16

53

13 (4)

15

25

Myxofibrosarcoma

21

30

14 (2)

8

8

Epithelioid sarcoma

10

23

7 (1)

15

1

Osteosarcoma

48

98

39 (7)

28

31

Clear cell sarcoma

6

8

5 (1)

3

0

Ewing sarcoma/DSRCT

31

120

20 (6)

47

53

Synovial sarcoma

26

44

17 (3)

24

3

De-differentiated liposarcoma

18

36

11 (1)

17

8

Solitary fibrous tumour

14

25

8 (1)

9

8

Chondrosarcoma grade 2/3

24

45

18 (1)

17

10

Myxoid/round cell liposarcoma

26

36

18 (4)

12

6

Alveolar soft part sarcoma

4

4

4 (1)

0

0

MPNST

37

65

33 (4)

21

11

Low grade soft tissue sarcoma

25

17

17 (0)

0

0

Chondrosarcoma grade 1

9

10

6 (0)

4

0

Total

493

957

344 (51)

369

244

  1. DSRCT desmoplastic small round cell sarcoma, MPNST malignant peripheral nerve sheath tumour, includes low-grade
  2. aNote this is overall detection of metastatic disease at initial CT and MRI staging only, ‘added value’ comparison is reported in Table 3
  3. bIncludes high grade ‘spindle cell sarcoma’
  4. cIncludes ‘high grade epitheloid haemangioendothelioma’